… all patients were treated with temozolomide. We focused on overall survival only, so are
unable to draw conclusions about using techniques to predict progression-free survival. The …

… While other tumors have responded favorably to trials combining immunotherapy and
chemotherapy, GBM remains uniformly deadly with minimal increases in overall survival. GBM …

… Primary endpoints were progression-free survival (PFS) and overall survival (OS). Continuous
variables were analyzed by ANOVA, and the Kaplan-Meier method was used to evaluate …

… The median overall survival was longer with temozolomide compared with standard
radiotherapy (8.3 vs 6.0 months), and equivalent to hypofractionated radiotherapy. In patients older …

… temozolomide within a low pH environment and demonstrate precise in vitro quantitative
release of temozolomide … prolonged overall survival, compared with standard-of-care treatment, …

… that combined lomustine-temozolomide chemotherapy plus radiotherapy could improve
overall survival compared with standard temozolomide chemotherapy plus radiotherapy. …

… GBM treatment. Recent emerging evidence from clinical trials suggests that a … treatment
of lomustine and TMZ may improve overall survival when used as a first-line treatment for …

… affects survival outcome has yet to be thoroughly evaluated in the current temozolomide (…
Prognostic hazard ratios (HRs) for overall survival (OS) derived from multivariate regression …

… Median overall survival (OS) was 11.2 … temozolomide treatment, the concomitant and the
adjuvant phases were analyzed separately, and the number of cycles of adjuvant temozolomide …

… given simultaneously with radiotherapy does not improve overall survival compared with
not giving temozolomide. Even more importantly, we found that the clinical benefit of adding …